Regeneron Pharmaceuticals, Inc. CEO Leonard Schleifer weighed in on the Federal Trade Commission’s attempt to block Amgen, Inc.’s $27.8bn acquisition of Horizon Therapeutics plc, taking the stage at the Financial Times US Pharma and Biotech Summit on 16 May moments after the FTC announced it would seek to block the merger on the basis of Amgen’s rebating practices to support the federal agency’s move.
Schleifer’s opinion of the FTC decision may be unexpected coming from a top pharma CEO, something not uncommon during the...








